WeShare Partners

Unicancer is the only French hospital network dedicated 100% to the fight against cancer and the only national hospital federation dedicated to cancer research.

It brings together 18 private, non-profit cancer centers (CLCCs) at 20 hospital sites in France, as well as two affiliated member institutions. The CLCCs provide care for nearly 530,000 patients per year (in short stay, HAH and outpatient procedures).
Unicancer is also the leading European academic sponsor of clinical trials in oncology, with 106 active clinical trials supported in 2020 and nearly 7,600 patients included. Unicancer also supports flagship programs that use real-life data to improve knowledge and the evaluation of therapeutic strategies, notably through the ESME platforms, which gather data from more than 76,000 cancer patients.

Recognized as a research leader in France, the Unicancer network boasts a global reputation by producing one third of French publications of international scope in oncology (source: bibliometric study/Thomson Reuters). In 2020, the Unicancer network sponsored up to 700 clinical trials (inclusion or follow-up), more than 14% of CLCC patients are included in clinical trials and more than half of the hospital-based clinical research programs (PHRC) are dedicated to CLCCs.

The 18 CLCCs and Unicancer's R&D department are ISO 9001:2015 certified for their clinical research.

Ranked as the leading European Cancer Centre and third in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer around four missions: prevention, care, research and education.

The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age.

Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected.

4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: a quarter of patients treated are included in clinical trials.

The Centre François Baclesse’s public health mission is threefold: healthcare, research and education in the exclusive field of oncology. 

Located in Caen, in Normandy, the Centre is a reference healthcare facility for cancer care, at regional, national and international level. The Centre François Baclesse is a comprehensive cancer centre. It’s a non-profit ‘private healthcare establishment of collective interest’ (ESPIC). 

Employing a total of 1,000 professionals, the Centre cares, every year, for around 27,500 patients 

Our strengths 

 The Centre boasts a high-technology technical platform that is renowned at national and European level and offers patients access to a top quality healthcare offer. 

The Centre’s researchers contribute towards research work by Inserm-certified associated research teams. 

• Innovative technical platforms: radiotherapy, proton therapy, diagnostic and interventional radiology, nuclear medicine, operating theatre, cancer biology and genetics, anatomopathology. 
• Innovative healthcare: fast care paths, anticipated chemotherapy preparation, personalised care based on biological profiles and healthcare paths, etc. 
• A vast supportive care offer, to benefit patient quality of life 
• A clinical research unit to monitor patients included in clinical trials and a certified early phase unit offering the opportunity to take part in the development of new molecules. 

The Léon Bérard Centre (CLB) is part of the twenty French Comprehensive Cancer Centres in France, providing a global management of cancer patients on a unique area, from diagnosis to treatment and beyond.
The Centre is a regional, national and international recognized reference cancer Centre assigned with three essential missions: Care, Research and Education and is willing to continuously improve the quality and accessibility of care for cancer patients.

More than 44,000 patients are received each year, on consultations or exams and 6,000 new cancer cases are diagnosed.
The CLB has technical and treatment facilities (operating room, radiation therapy centre, medical imaging departments, pathology and nuclear medicine departments).

[The bench-to-bedside process is one of the strength of the Centre Léon Bérard]
The Centre Léon Bérard develops an excellence and multidisciplinary research, in association with the cares carried out on site and institutional and private partners.
The foundations of this development lay in the medical and scientific project. The CLB aims to reinforce the bench-to-bedside process by facilitating translational research to help innovation and speed-up its access to patients for diagnoses and therapies.
Clinical research has been certified ISO 9001 since 2013 and is thus one of the strength of the Centre.
As a result, more than 22% of patients were included in clinical trials in 2020.
At the Centre Léon Bérard 2,200 persons work in cares, research, education and supportive care (280 physicians, 500 researchers, 800 caregivers).

ABOUT ÉCOLE POLYTECHNIQUE / École polytechnique, also known as L’X, is the leading French institution combining top-level research, academics, and innovation at the cutting-edge of science and technology. Its various undergraduate and graduate-level programs – Bachelor of Science, Ingénieur Polytechnicien (Master’s level program), Master’s, and PhD – are highly selective and promote a culture of excellence with a strong emphasis on science, anchored in humanist traditions. As a widely internationalized university, École polytechnique offers a variety of international programs and attracts a growing number of foreign students and researchers from around the globe (currently 41% of students and 40% of faculty members). École polytechnique offers an exceptional education to prepare bright men and women to excel in top-level key positions and lead complex and innovative projects which meet the challenges of 21st century society, all while maintaining a keen sense of their civil and social responsibilities. With its 23 laboratories, 22 of which are joint research units with the French National Center for Scientific Research (CNRS), the École polytechnique Research Center explores the frontiers of interdisciplinary knowledge to provide major contributions to science, technology, and society. École Polytechnique is a founding member of Institut Polytechnique de Paris.

Founded in 1972 by the Ecole polytechnique, CRG (Management Research Center) is the first laboratoire dedicated to research in management to have been recognized by the CNRS in 1980. Research on health management has been carried out there since the origins of the laboratory.  Etienne Minvielle is the current head of the CRG.

Seintinelles is a charity. Its vocation is to improve the care and the QoL of all people directly or indirectly affected by cancer, thanks to a cancer research moving faster and being closer to the citizen needs.

Our added value is to use digital tools and proven marketing technics , to engage citizens and researchers in a direct, constructive and productive collaboration.

We are working on all cancer, so far only with academic research

And it works.

We have a database of more than 38 000 citizens. Previous patients, patients, patient’s family members or only citizen willing to help. Those citizens took part to more than 45 researches and generated for those researches 48 000 participations, leading to 26 scientific articles.

Our next challenges.

• Find the right partners to have a more diverse community of potential participants.
• Be an enabler for a co-built research at a large scale
• Expand our impact beyond Cancer and beyond France.

The Quality of Life and Cancer Clinical Research National Platform is a network of French researchers in oncology research involved in exchanges and scientific reflections about the quality of life in oncology. The expertise of the 25 hospital and university partner units of the Platform covers the human, economic and social sciences, the clinic, epidemiology, methodology and psychometry.

The scientific activities of the Quality of Life and Cancer National Platform are centered on methodological and statistical support in the context of clinical trials, epidemiological studies or in the human and social sciences, but also on the development of research around quality of life, as well as the improvement of its evaluation in order to obtain robust, comparable and explicit results allowing to formulate recommendations for public health and clinical practices.

The main research areas supported by the Platform : 

• Conceptual development and integrative approaches to quality of life
• Validation, selection and use of quality of life questionnaires
• Longitudinal analyses of quality of life
• Prognostic value of quality of life and relation to clinical criteria

For 15 years, the Quality of Life and Cancer Clinical Research National Platform has been certified by the National League Against Cancer and benefits from the institutional support of INCa and its Canceropoles.

The general activity of the Platform is under the responsibility of Pr. Francis Guillemin, coordinator of the CIC-EC, Inserm CIC 1433 of the CHRU of Nancy, and of Pr. Pascal Auquier, director of the Center for Studies and Research on Health Services and Quality of Life of the University of Marseille. The missions of the Secretary General of the Platform are entrusted to Dr Sandrine Dabakuyo Yonli (PhD, HDR), Head of the Research Unit in Epidemiology and Quality of Life of the Georges-François Leclerc Center in Dijon.